Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
<p>Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells</p>
Spremljeno u:
| Glavni autor: | |
|---|---|
| Daljnji autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Izdano: |
2025
|
| Teme: | |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|